Adaptive Biotechnologies Corp
ADPT
Market Cap$380.14M
Close$
$3.64
32.4% upside
Current Fair Value
32.4% upsideUndervalued by 32.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $380.14 Million |
|---|---|
| Enterprise Value | $33.74 Million |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-1.56 |
| Beta | 2.11 |
| Outstanding Shares | 145,092,271 |
| Avg 30 Day Volume | 1,605,942 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -1.69 |
|---|---|
| PEG | -2.31 |
| Price to Sales | 2.75 |
| Price to Book Ratio | 1.38 |
| Enterprise Value to Revenue | 0.2 |
| Enterprise Value to EBIT | -0.17 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
ESG Score
No data
About Adaptive Biotechnologies Corp
CEO: Chad Robins Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Adaptive Biotechnologies believes the adap...